Comparative Pharmacology
Head-to-head clinical analysis: BRETYLIUM TOSYLATE versus BRETYLIUM TOSYLATE IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRETYLIUM TOSYLATE versus BRETYLIUM TOSYLATE IN DEXTROSE 5 IN PLASTIC CONTAINER.
BRETYLIUM TOSYLATE vs BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bretylium tosylate is a class III antiarrhythmic agent that prolongs the action potential duration and refractory period by blocking potassium channels. It also initially causes norepinephrine release, leading to transient hypertension and increased contractility, followed by adrenergic neuron blockade, resulting in hypotension and reduced contractility.
Bretylium tosylate inhibits norepinephrine release from adrenergic nerve terminals by blocking neuronal reuptake and causing initial norepinephrine release followed by depletion. It also exhibits class III antiarrhythmic activity by prolonging the action potential duration and refractory period in cardiac Purkinje fibers and ventricular muscle.
For ventricular tachycardia/fibrillation: 5-10 mg/kg IV bolus over 1-2 minutes, may repeat every 15-30 minutes up to 30 mg/kg total. Maintenance: 5-10 mg/kg IV every 6 hours or 0.5-2 mg/min continuous infusion. Intramuscular: 5-10 mg/kg undiluted, may repeat every 1-2 hours.
For ventricular tachycardia/fibrillation: 5 mg/kg IV over 8-10 minutes, then 5-10 mg/kg IV q6-8h. For continuous infusion: 1-2 mg/min IV.
None Documented
None Documented
5-10 hours; prolonged in renal impairment (up to 30 hours)
Terminal half-life: 7-11 hours (normal renal function); prolonged in renal impairment (up to 16-32 hours in anuria)
Renal: ~80% unchanged; biliary/fecal: <1%
Renal: >80% unchanged; biliary/fecal: minimal (<5%)
Category C
Category C
Antiarrhythmic (Class III)
Antiarrhythmic (Class III)